Supplementary Figure 3: Genetic or pharmacologic CDK9 inhibition promotes proteasome inhibitor (PI) lethality in bortezomib-sensitive MM cells. (A)
U266 cells were treated with btz (2 nM) or cfz (5 nM) with or without dinaciclib (SCH; 7 nM) for 24 hr, and then analyzed by flow cytometry to determine the percentage of apoptotic cells. Cell death (7-AAD) was analyzed by flow cytometry. Significantly greater than control; ** = P < 0.01. (B) U266 cells were treated with btz (2 nM) or cfz (5 nM) with or without alvocidib (FP; 150 nM) for 24 hr, and then analyzed by flow cytometry to determine the percentage of apoptotic cells. Significantly greater than control; ** = P < 0.01.
Supplementary Figure 4: Dinaciclib markedly increases HA-14-induced cell death in both sensitive and bortezomibresistant MM cells. (A)
RPMI8226 cells were exposed to dinaciclib (SCH; 10 nM) with or without HA-14 (1μM) for 3 hr, followed by flow cytometry to monitor the percentage of apoptotic (Annexin V+) cells. (B) RPMI8226 cells were exposed to SCH 10 nM or 15 nM with or without HA-14 1μM for 3 hr, after which cell extracts were immunoblotted to monitor expression of Mcl-1, Bcl-xL, Bcl-2, and cleaved caspase 9, caspase 3, and PARP. α-tubulin controls were assayed to ensure equivalent loading and transfer. (C) U266 and PS-R cells were exposed to SCH 10 nM with or without HA-14 (1μM) for 24 hr, after which cell death was analyzed by flow cytometry after staining with 7-AAD. Values represent means ± S.D. for three replicate determinations. *** = P < 0.001, significantly greater than values for individual agents. , all mice were euthanized, and tumors removed and subjected to immunoblot analysis for phosphorylated CTD (serine-2) and Mcl-1 levels. Each lane was loaded with 30 μg of protein, and α-tubulin controls were assayed to ensure equivalent loading and transfer.
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